(BNTX) |
| 0 (0%) 04-14 05:00 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 120.13 |
| Resistance 1: | 102.86 |
| Pivot price: | 89.93 |
| Support 1: | 88.43 |
| Support 2: | 79.52 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -5.430 |
| Book Value | 88.230 |
| PEG Ratio | 0.00 |
| Gross Profit | 8.992 |
| Profit Margin (%) | -39.59 |
| Operating Margin (%) | -33.35 |
| Return on Assets (ttm) | -3.6 |
| Return on Equity (ttm) | -5.9 |
Company news
Mon, 13 Apr 2026
BioNTech (BNTX) CEO discloses 39.2M indirect ordinary shares - Stock Titan
Mon, 13 Apr 2026
Berenberg Bank Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $155 - Moomoo
Mon, 13 Apr 2026
Endometrial cancer trial: BioNTech (Nasdaq: BNTX) ADC hits Phase 2 goal - Stock Titan
Mon, 13 Apr 2026
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data - Sahm
Mon, 13 Apr 2026
BioNTech (BNTX) PT Raised to $130 at BofA Securities - StreetInsider
Sun, 12 Apr 2026
BioNTech (BNTX) Reports Encouraging Phase 2 Results for Cancer T - GuruFocus
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
